Its portfolio includes insulin analogs, GLP-1 receptor agonists, and oral antidiabetic drugs like Rybelsus ... and Optum Rx grew by 15% to over $130 billion due to strong client retention and ...
The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback